div class=ts-pagebuttonPage 1button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page1jpg target=_blank amp-img class=ts-thumb alt=Page 1: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divpNuevas opciones en segunda línea de cáncer de páncreasp pTeresa Macarullap pHospital Vall d´Hebrónp pBracelonapdivdiv class=ts-pagebuttonPage 2button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page2jpg target=_blank amp-img class=ts-thumb alt=Page 2: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 3button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page3jpg target=_blank amp-img class=ts-thumb alt=Page 3: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 4button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page4jpg target=_blank amp-img class=ts-thumb alt=Page 4: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 5button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page5jpg target=_blank amp-img class=ts-thumb alt=Page 5: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails5jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 6button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page6jpg target=_blank amp-img class=ts-thumb alt=Page 6: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails6jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 7button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page7jpg target=_blank amp-img class=ts-thumb alt=Page 7: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails7jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 8button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page8jpg target=_blank amp-img class=ts-thumb alt=Page 8: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails8jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 9button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page9jpg target=_blank amp-img class=ts-thumb alt=Page 9: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails9jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 10button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page10jpg target=_blank amp-img class=ts-thumb alt=Page 10: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails10jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 11button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page11jpg target=_blank amp-img class=ts-thumb alt=Page 11: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails11jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 12button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page12jpg target=_blank amp-img class=ts-thumb alt=Page 12: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails12jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 13button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page13jpg target=_blank amp-img class=ts-thumb alt=Page 13: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails13jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 14button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page14jpg target=_blank amp-img class=ts-thumb alt=Page 14: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails14jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 15button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page15jpg target=_blank amp-img class=ts-thumb alt=Page 15: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails15jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 16button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page16jpg target=_blank amp-img class=ts-thumb alt=Page 16: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails16jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 17button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page17jpg target=_blank amp-img class=ts-thumb alt=Page 17: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails17jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 18button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page18jpg target=_blank amp-img class=ts-thumb alt=Page 18: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails18jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 19button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page19jpg target=_blank amp-img class=ts-thumb alt=Page 19: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails19jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 20button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page20jpg target=_blank amp-img class=ts-thumb alt=Page 20: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails20jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 21button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page21jpg target=_blank amp-img class=ts-thumb alt=Page 21: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails21jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 22button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page22jpg target=_blank amp-img class=ts-thumb alt=Page 22: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails22jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 23button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page23jpg target=_blank amp-img class=ts-thumb alt=Page 23: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails23jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 24button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page24jpg target=_blank amp-img class=ts-thumb alt=Page 24: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails24jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 25button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page25jpg target=_blank amp-img class=ts-thumb alt=Page 25: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails25jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 26button div class=ts-image a href=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5page26jpg target=_blank amp-img class=ts-thumb alt=Page 26: Presentación de PowerPoint - forodebateoncologianet · 64 m 111m 484% 186% Median follow-up 266 mo 95% Cl 205-449 OS analysis based on 273 deaths among 342 patients 798% src=https:reader039vdocumentscoreader039viewer20220219115c3993de09d3f2fd328c4fe7html5thumbnails26jpg width=142 height=106 layout=responsive amp-imga divdiv